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Introduction
Acute respiratory distress syndrome (ARDS) is charac-
terized by damage to the alveolar epithelial-endothelial
barrier resulting in neutrophil influx and pulmonary
oedema. The activation of platelet and secondary cap-
ture of neutrophils may play an important role in propa-
gation of inflammation in ARDS [1]. Various animal
studies have shown that aspirin therapy reduces pul-
monary oedema and development of lung injury [2]. In
observational studies, patients on aspirin therapy prior
to hospital admission had a reduced incidence of ARDS
[3]. By acetylating cyclooxygenase, aspirin inhibits plate-
let aggregation and generates anti-inflammatory mole-
cules which modulate neutrophilic inflammation [4].
Objective
To test the hypothesis that aspirin reduces pulmonary
inflammation in an in vivo human model of acute
respiratory distress syndrome, induced by inhaled lipo-
polysaccharide (LPS).
Methods
Healthy subjects were enrolled in a double-blind,
placebo-controlled study and were randomised to receive
aspirin 75mg or aspirin 1200mg or placebo (1:1:1) for
seven days prior to LPS inhalation. Measurements were
performed in bronchoalveolar lavage (BAL) fluid
obtained at 6 hours after inhaling 50 micrograms of LPS.
Results
33 healthy subjects were enrolled. There was no signifi-
cant difference between aspirin 75mg and aspirin
1200mg. Data for both aspirin groups were combined.
Aspirin pre-treatment reduced LPS induced BAL neutro-
philia (figure 1) and BAL concentrations of both the
neutrophil-specific protease MMP-8, and the pro-inflam-
matory cytokine TNF-a. There was a non-significant
trend towards reduction in a range of inflammatory cyto-
kines (table 1).
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Figure 1 Aspirin reduces LPS induced BAL neurtophilia.
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Conclusion
This study shows for the first time that aspirin can
reduce neutrophilic inflammation in the lung in humans.
Further clinical studies are warranted to assess its ability
to reduce neutrophil mediated inflammation in ARDS.
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Table 1 Effect of aspirin on markes of pulmonary inflammation
BAL
Placebo (n=13) Aspirin (n=20) % reduction p-value
PMN (105cells/ml) 2.25 (1.18, 4.67) 1.48 (0.32, 6.21) 34.2 0.03
TNF-a (pg/ml) 105.7 (73.49, 358.5) 79.72 (37.34, 276.6) 24.5 0.02
IL-6 (pg/ml) 856.5 (535.9, 2285) 647.9 (224.6, 1582) 24.1 0.07
MMP-8 (pg/ml) 6342 (1932, 9574) 2902 (862.8, 6758) 54 0.03
MMP-9 (pg/ml) 48493 (23126, 99780) 33717 (10471, 72334) 30.4 0.03
IL-8 (pg/ml) 447.5 (236.9, 1250) 345.9 (175.5, 1522) 22.7 0.11
IL-1b (pg/ml) 42.74 (25.98, 98.76) 37.03 (18.73, 54.88) 13 0.16
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